Correction of Fanconi Anemia Mutations Using Digital Genome Engineering
Authors:
- Christopher J. SipeCSChristopher J. Sipe
- Mitchell G. KluesnerMKMitchell G. Kluesner
- Samuel P. BingeaSBSamuel P. Bingea
- Walker S. LahrWLWalker S. Lahr
- Aneesha A. AndrewAAAneesha A. Andrew
- Minjing WangMWMinjing Wang
- Anthony P. DeFeoADAnthony P. DeFeo
- Timothy L. HinkelTHTimothy L. Hinkel
- Kanut LaoharaweeKLKanut Laoharawee
- John E. WagnerJWJohn E. Wagner
- Margaret L. MacMillanMMMargaret L. MacMillan
- Gregory M. VercellottiGregory M. Vercellotti
Open Access
- 29 July 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8416
Abstract
Fanconi anemia (FA) is a rare genetic disease in which genes essential for DNA repair are mutated. Both the interstrand crosslink (ICL) and double-strand break (DSB) repair pathways are disrupted in FA, leading to patient bone marrow failure (BMF) and cancer predisposition. The only curative therapy for the hematological manifestations of FA is an allogeneic hematopoietic cell transplant (HCT); however, many (>70%) patients lack a suitable human leukocyte antigen (HLA)-matched donor, often resulting in increased rates of graft-versus-host disease (GvHD) and, potentially, the exacerbation of cancer risk. Successful engraftment of gene-corrected autologous hematopoietic stem cells (HSC) circumvents the need for an allogeneic HCT and has been achieved in other genetic diseases using targeted nucleases to induce site specific DSBs and the correction of mutated genes through homology-directed repair (HDR). However, this process is extremely inefficient in FA cells, as they are inherently deficient in DNA repair. Here, we demonstrate the correction of FANCA mutations in primary patient cells using ‘digital’ genome editing with the cytosine and adenine base editors (BEs). These Cas9-based tools allow for C:G > T:A or A:T > C:G base transitions without the induction of a toxic DSB or the need for a DNA donor molecule. These genetic corrections or conservative codon substitution strategies lead to phenotypic rescue as illustrated by a resistance to the alkylating crosslinking agent Mitomycin C (MMC). Further, FANCA protein expression was restored, and an intact FA pathway was demonstrated by downstream FANCD2 monoubiquitination induction. This BE digital correction strategy will enable the use of gene-corrected FA patient hematopoietic stem and progenitor cells (HSPCs) for autologous HCT, obviating the risks associated with allogeneic HCT and DSB induction during autologous HSC gene therapy.Keywords
Funding Information
- Fanconi Anemia Research Fund (FARF) (T32GM007266)
- University of Minnesota-Fairview Academic Investment Research Program (AIRP) (T32GM007266)
- Children’s Cancer Research Foundation (CCRF) (T32GM007266)
- University of Minnesota’s Department of Pediatrics ‘R’ Award (T32GM007266)
- University of Minnesota’s Stem Cell Institute INFUSE (T32GM007266)
- NIH (T32GM007266)
This publication has 56 references indexed in Scilit:
- VACTERL-H Association and Fanconi AnemiaMolecular Syndromology, 2012
- Playing the End Game: DNA Double-Strand Break Repair Pathway ChoiceMolecular Cell, 2012
- Bone Marrow Failure in Fanconi Anemia Is Triggered by an Exacerbated p53/p21 DNA Damage Response that Impairs Hematopoietic Stem and Progenitor CellsCell Stem Cell, 2012
- How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and IsraelAmerican Journal of Medical Genetics Part A, 2011
- Cellular Therapy for Fanconi Anemia: The Past, Present, and FutureTransplantation and Cellular Therapy, 2011
- The Fanconi anemia pathway promotes DNA glycosylase‐dependent excision of interstrand DNA crosslinksEnvironmental and Molecular Mutagenesis, 2010
- Diagnosis of Fanconi anemia in patients with bone marrow failureHaematologica, 2009
- Stem Cell Collection and Gene Transfer in Fanconi AnemiaMolecular Therapy, 2007
- Successful engraftment without radiation after fludarabine‐based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantationPediatric Blood & Cancer, 2005
- A common founder mutation in FANCA underlies the world's highest prevalence of Fanconi anemia in Gypsy families from SpainBlood, 2005